EPRX (eupraxiapharma.com) Future Price to Earnings

Official company branding of Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals (EPRX) is developing innovative methods for prolonging drug action. The absence of commercialized products and a focus on delivery system testing make scaling impossible, while research expenditures result in losses. The stock price history reflects the P/E ratio dynamics, which currently stands at 0.00. The company's prospects rely on the success of the EP-104 drug for osteoarthritis and the implementation of its platform within the oncology sphere.

Eupraxia Pharmaceuticals - EPRX Market Cap to Future Earnings Ratio (period 04/06/2024 - 11/17/2026)

Summary analytical data breakdowns for eupraxiapharma.com (EPRX)

Fundamental valuation:Eupraxia Pharmaceuticals Inc.
Brand item of Eupraxia Pharmaceuticals

Forward P/E measures the market premium for expected net income growth, determining the cost of a single unit of projected earnings. An investor compares this ratio with the fundamental stability of assets to assess whether an asset is overbought. The forward P/E history of Eupraxia Pharmaceuticals (EPRX) visualizes the trend of the stock's attractiveness to institutional capital. For Eupraxia Pharmaceuticals (EPRX), this metric reflects the market's confidence in the monetization of its patented extended-release technologies. High barriers to entry in biopharmaceuticals justify long-term profit expectations.

Competitors of Eupraxia Pharmaceuticals (EPRX)

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Biopharma)|AQST (aquestive.com) - Projected Price to Earnings|Price to Expected Earnings Ratio SCPH (scPharmaceuticals, Inc.)|Projected Price to Earnings TECX|Tonix Pharmaceuticals (TNXP) - Market Cap to Projected Earnings|Forward P/E Multiple SXTC|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP